Literature DB >> 17227126

Analysis of loss of heterozygosity in atypical and negative bile duct brushing cytology specimens with malignant outcome: are "false-negative" cytologic findings a representation of morphologically subtle molecular alterations?

Uma Krishnamurti1, Eizaburo Sasatomi, Patricia A Swalsky, Sydney D Finkelstein, N Paul Ohori.   

Abstract

CONTEXT: Conventional cytologic evaluation of bile duct brushings for neoplasia has high specificity but relatively low sensitivity.
OBJECTIVE: The aim of this pilot study was to examine whether K-ras mutations and loss of heterozygosity for multiple microsatellite markers in bile duct brushings would contribute to the detection of malignancy in cases initially reported as "negative" or "atypical."
DESIGN: Bile duct brushing specimens with a negative or an atypical cytologic result (9 cases) had a benign result on the surgical pathology specimen, and 9 additional negative or atypical cases demonstrated adenocarcinoma on the resected surgical specimen. Cells from representative cytopathology and histology slides were microdissected and analyzed for K-ras mutations and for loss of heterozygosity with a panel of 15 polymorphic markers on chromosomes 1p, 3p, 5q, 9p, 9q, 10q, 17p, and 22q.
RESULTS: Among cytology cases with malignant outcome, loss of heterozygosity or K-ras mutation was detected in 8 (88.8%) of 9 cases. In the corresponding 9 surgical pathology specimens with adenocarcinoma, K-ras mutations and/or allelic losses were detected in all (100%). Loss of heterozygosity or K-ras mutation was not detected in cytology cases that had a benign surgical outcome. The fractional allelic loss of these 9 cytology specimens ranged from 0 to 0.25 (mean, 0.14). This compared with the fractional allelic loss ranging from 0.15 to 0.42 (mean, 0.27) for the corresponding surgical specimens.
CONCLUSIONS: This pilot study suggests that low-level fractional allelic loss or K-ras mutation in the negative/atypical cytology samples with malignant outcome is a representation of morphologically subtle molecular alterations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17227126     DOI: 10.5858/2007-131-74-AOLOHI

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  2 in total

1.  Mutational analysis of cytocentrifugation supernatant fluid from pancreatic solid mass lesions.

Authors:  Sydney D Finkelstein; Marluce Bibbo; Thomas E Kowalski; David E Loren; Ali A Siddiqui; Charalambos Solomides; Eric Ellsworth
Journal:  Diagn Cytopathol       Date:  2013-11-22       Impact factor: 1.582

2.  The added value of using mutational profiling in addition to cytology in diagnosing aggressive pancreaticobiliary disease: review of clinical cases at a single center.

Authors:  Nidhi Malhotra; Sara A Jackson; Lindsay L Freed; Mindi A Styn; Mary K Sidawy; Nadim G Haddad; Sydney D Finkelstein
Journal:  BMC Gastroenterol       Date:  2014-08-01       Impact factor: 3.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.